SOUTH PLAINFIELD, N.J.
June 11, 2014
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of
Ronald C. Renaud, Jr.
to the company's Board of Directors. Mr. Renaud has served as the President and Chief Executive Officer of Idenix Pharmaceuticals, Inc., a public biopharmaceutical company, since
"We are delighted to welcome Ron to PTC's Board of Directors. Ron brings tremendous skills and experience to PTC that will be invaluable to our future growth and success. His demonstrated leadership experience in building successful biotechnology companies, his former background as an equity research analyst and his deep knowledge of the life sciences industry will provide valuable contributions to our company," said
Stuart W. Peltz
, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc.
Mr. Renaud previously served as the Chief Financial Officer of Idenix from the time he joined Idenix in
and was additionally appointed chief business officer in
. Prior to joining Idenix, Mr. Renaud served as senior vice president and chief financial officer of Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, from
. He was a senior research analyst and global sector coordinator for JP Morgan Securities from
, where he was responsible for the biotechnology equity research effort, covering all ranges of capitalized biotechnology companies. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. Mr. Renaud holds a B.A. from
St. Anselm College
and an M.B.A. from the Marshall School of Business at the
University of Southern California
"I am thrilled to join PTC during this exciting time in the company's history," said Mr. Renaud. "I look forward to supporting the commercialization of Translarna™ in the EU, the advancement of Translarna™ in the US, as well as the continued growth and development of PTC's broad pipeline."